Clinical Characteristics and Outcome of Ceftazidime/Avibactam-Resistant
KPC variant
carbapenems
ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae
ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae
meropenem/vaborbactam
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
20
03
2023
accepted:
26
06
2023
medline:
21
7
2023
pubmed:
21
7
2023
entrez:
21
7
2023
Statut:
epublish
Résumé
Recently, From 2019 to 2021, a retrospective 2-center study including patients with infections due to CZA-R KPC-Kp hospitalized at 2 academic hospitals in Rome was conducted. Demographic and clinical characteristics were collected. Principal outcome was 30-day all-cause mortality. Statistical analyses were performed with Stata-IC17 software. Overall, 59 patients were included (mean age, 64.4 ± 14.6 years; mean Charlson comorbidity index score, 4.5 ± 2.7). Thirty-four patients (57.6%) had infections caused by CZA-R and meropenem (MEM)-susceptible strains. A previous CZA therapy was observed in 40 patients (67.8%), mostly in patients with MEM-susceptible KPC variant (79.4% vs 52%, Infections due to CZA-R KPC-Kp often occur in patients who had previously received CZA, especially in the presence of strains susceptible to MEM. Nevertheless, one-third of patients had never received CZA before KPC-Kp CZA-R. Since the major driver for mortality was infection severity, understanding the optimal therapy in patients with KPC-Kp CZA-R infections is of crucial importance.
Sections du résumé
Background
UNASSIGNED
Recently,
Methods
UNASSIGNED
From 2019 to 2021, a retrospective 2-center study including patients with infections due to CZA-R KPC-Kp hospitalized at 2 academic hospitals in Rome was conducted. Demographic and clinical characteristics were collected. Principal outcome was 30-day all-cause mortality. Statistical analyses were performed with Stata-IC17 software.
Results
UNASSIGNED
Overall, 59 patients were included (mean age, 64.4 ± 14.6 years; mean Charlson comorbidity index score, 4.5 ± 2.7). Thirty-four patients (57.6%) had infections caused by CZA-R and meropenem (MEM)-susceptible strains. A previous CZA therapy was observed in 40 patients (67.8%), mostly in patients with MEM-susceptible KPC variant (79.4% vs 52%,
Conclusions
UNASSIGNED
Infections due to CZA-R KPC-Kp often occur in patients who had previously received CZA, especially in the presence of strains susceptible to MEM. Nevertheless, one-third of patients had never received CZA before KPC-Kp CZA-R. Since the major driver for mortality was infection severity, understanding the optimal therapy in patients with KPC-Kp CZA-R infections is of crucial importance.
Identifiants
pubmed: 37476077
doi: 10.1093/ofid/ofad327
pii: ofad327
pmc: PMC10354859
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofad327Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. All authors: No reported conflicts.
Références
Folia Microbiol (Praha). 2021 Dec;66(6):879-896
pubmed: 34505209
J Antimicrob Chemother. 2019 Aug 1;74(8):2464-2466
pubmed: 31318973
Open Forum Infect Dis. 2017 Jul 01;4(3):ofx101
pubmed: 28685153
Lancet Infect Dis. 2017 Jul;17(7):726-734
pubmed: 28442293
Microorganisms. 2021 Nov 15;9(11):
pubmed: 34835481
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Crit Care. 2020 Jan 30;24(1):29
pubmed: 32000834
Clin Microbiol Infect. 2020 Jan;26(1):124.e1-124.e4
pubmed: 31494252
J Glob Antimicrob Resist. 2021 Jun;25:268-281
pubmed: 33895414
Infect Dis Ther. 2021 Dec;10(4):1989-2034
pubmed: 34379310
Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0116021
pubmed: 34606331
J Glob Antimicrob Resist. 2020 Sep;22:18-27
pubmed: 31863899
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
BMC Microbiol. 2021 Aug 19;21(1):230
pubmed: 34412588
Antimicrob Agents Chemother. 2015 Sep;59(9):5324-30
pubmed: 26100712
Lancet Infect Dis. 2016 Jul;16(7):819-827
pubmed: 26947523
Clin Infect Dis. 2021 Nov 2;73(9):1664-1676
pubmed: 33618353
Clin Microbiol Infect. 2020 Apr;26(4):516.e1-516.e4
pubmed: 31740422
Clin Microbiol Infect. 2021 Aug;27(8):1172.e7-1172.e10
pubmed: 33915286
Microb Genom. 2023 Feb;9(2):
pubmed: 36752778
Antimicrob Agents Chemother. 2017 Apr 24;61(5):
pubmed: 28242667
Antimicrob Agents Chemother. 2018 Apr 26;62(5):
pubmed: 29507064
J Infect Dis. 1980 Jun;141(6):781-6
pubmed: 6993589
Clin Infect Dis. 2016 Dec 15;63(12):1615-1618
pubmed: 27624958
JAC Antimicrob Resist. 2022 Dec 07;4(6):dlac121
pubmed: 36506890
J Glob Antimicrob Resist. 2020 Sep;22:9-12
pubmed: 31733412
Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0057421
pubmed: 34339281
Clin Microbiol Infect. 2022 May;28(5):749-751
pubmed: 35124257
Antimicrob Agents Chemother. 2017 Feb 23;61(3):
pubmed: 28031201
Clin Microbiol Infect. 2021 Jul;27(7):1040.e1-1040.e6
pubmed: 33775814
Emerg Microbes Infect. 2021 Dec;10(1):2042-2051
pubmed: 34551677
Eur J Clin Microbiol Infect Dis. 2022 Mar;41(3):495-500
pubmed: 34988712
J Infect Chemother. 2021 May;27(5):778-780
pubmed: 33558042
Infect Dis Clin North Am. 2020 Dec;34(4):773-819
pubmed: 33011051
Antimicrob Agents Chemother. 2017 Apr 24;61(5):
pubmed: 28223379
Antimicrob Agents Chemother. 2020 Mar 24;64(4):
pubmed: 32015028
J Antimicrob Chemother. 2015 Aug;70(8):2279-86
pubmed: 25957381
J Chemother. 2021 Dec;33(8):598-600
pubmed: 33843501
Antimicrob Agents Chemother. 2015 Oct;59(10):6605-7
pubmed: 26195508
J Glob Antimicrob Resist. 2023 Jun;33:321-327
pubmed: 37086891
Clin Microbiol Infect. 2023 Apr;29(4):537.e1-537.e8
pubmed: 36414199
JAMA. 2020 Jun 2;323(21):2160-2169
pubmed: 32484534
JAC Antimicrob Resist. 2022 Mar 07;4(1):dlac022
pubmed: 35265842
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0089021
pubmed: 34228551